{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T05:57:14Z","timestamp":1743055034534,"version":"3.40.3"},"publisher-location":"Totowa, NJ","reference-count":41,"publisher":"Humana Press","isbn-type":[{"type":"print","value":"9781603275460"},{"type":"electronic","value":"9781603275477"}],"license":[{"start":{"date-parts":[[2008,10,13]],"date-time":"2008-10-13T00:00:00Z","timestamp":1223856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2008,10,13]],"date-time":"2008-10-13T00:00:00Z","timestamp":1223856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009]]},"DOI":"10.1007\/978-1-60327-547-7_22","type":"book-chapter","created":{"date-parts":[[2008,11,7]],"date-time":"2008-11-07T16:52:37Z","timestamp":1226076757000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Targeting of Gene Expression by siRNAs Directed Against BCR-ABL Transcripts in a Patient with Imatinib-Resistant Chronic Myeloid Leukemia"],"prefix":"10.1007","author":[{"given":"Michael","family":"Koldehoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet H.","family":"Elmaagacli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,13]]},"reference":[{"key":"22_CR1_22","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"J.M. Goldmann","year":"2003","unstructured":"Goldmann, J.M. and Melo, J.V. (2003) Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451\u20131461.","journal-title":"N. Engl. J. Med"},{"key":"22_CR2_22","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","volume":"88","author":"J.V Melo","year":"1996","unstructured":"Melo, J.V. (1996) The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88, 2375\u20132384.","journal-title":"Blood"},{"key":"22_CR3_22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean, M., Fojo, T., and Bates, S. (2005) Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275\u2013284.","journal-title":"Nat. Rev. Cancer"},{"key":"22_CR4_22","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1046\/j.1365-2141.2001.02858.x","volume":"113","author":"A.H Elmaagacli","year":"2001","unstructured":"Elmaagacli, A.H., Freist, A., Hahn, M., et al. (2001) Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of bcr-abl fusion transcripts detected using a new real-time polymerase chain reaction method. Br. J. Haemtol. 113, 1072\u20131075.","journal-title":"Br. J. Haemtol"},{"key":"22_CR5_22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/shem.2003.50037","volume":"40","author":"R. Capdeville","year":"2003","unstructured":"Capdeville, R. and Silberman, S. (2003) Imatinib: a targeted clinical drug development. Semin. Hematol. 40, 15\u201320.","journal-title":"Semin. Hematol"},{"key":"22_CR6_22","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1200\/jco.2006.24.18_suppl.6506","volume":"24","author":"B.J Druker","year":"2006","unstructured":"Druker, B.J., Guilhot, F., O\u2019Brien, R.A., et al. (2006) Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. J. Clin. Oncol. 24, 6506.","journal-title":"J. Clin. Oncol"},{"key":"22_CR7_22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00277-005-1039-z","volume":"84","author":"R Hehlmann","year":"2005","unstructured":"Hehlmann, R., Berger, U., and Hochhaus, A. (2005) Chronic myeloid leukemia: a model for oncology. Ann. Hematol. 84, 487\u2013497.","journal-title":"Ann. Hematol"},{"key":"22_CR8_22","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1182\/blood-2002-03-0675","volume":"100","author":"A Gratwohl","year":"2002","unstructured":"Gratwohl, A., Baldomero, H., Horisberger, B., et al. (2002) Current trends in hematopoietic stem cell transplantation in Europe. Blood 100, 2374\u20132386.","journal-title":"Blood"},{"key":"22_CR9_22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428190500407996","volume":"47","author":"J. Goldman","year":"2006","unstructured":"Goldman, J. and Gordon, M. (2006) Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk.  Lymphoma 47, 1\u20137.","journal-title":"Lymphoma"},{"key":"22_CR10_22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire, A., Xu, S., Montgomery, M.K., et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806\u2013811.","journal-title":"Nature"},{"key":"22_CR11_22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"S.M Elbashir","year":"2001","unstructured":"Elbashir, S.M., Harborth, J., Lendeckel, W., et al. (2001) Duplexes of 21- nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494\u2013498.","journal-title":"Nature"},{"key":"22_CR12_22","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1093\/nar\/30.10.e46","volume":"30","author":"O. Donze","year":"2002","unstructured":"Donze, O. and Picard, D. (2002) RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res. 30, e46.","journal-title":"Nucleic Acids Res"},{"key":"22_CR13_22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nrg1323","volume":"5","author":"V Mittal","year":"2004","unstructured":"Mittal, V. (2004) Improving the efficiency of RNA interference in mammals. Nat. Rev. Genet. 5, 355\u2013365.","journal-title":"Nat. Rev. Genet"},{"key":"22_CR14_22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0092-8674(03)00759-1","volume":"115","author":"D.S Schwarz","year":"2003","unstructured":"Schwarz, D.S., Hutv\u00e1gner, G., Du, T., et al. (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199\u2013208.","journal-title":"Cell"},{"key":"22_CR15_22","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1182\/blood-2002-06-1685","volume":"101","author":"M Scherr","year":"2003","unstructured":"Scherr, M., Battmer, K., Winkler, T., et al. (2003) Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101, 1566\u20131569.","journal-title":"Blood"},{"key":"22_CR16_22","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1182\/blood-2002-12-3899","volume":"102","author":"L Wohlbold","year":"2003","unstructured":"Wohlbold, L., van der Kuip, H., Miething, C., et al. (2003) Inhibition of bcr-abl gene expression by small interfering RNA sensitzes for imatinib mesylate (ST571). Blood 102, 2236\u20132239.","journal-title":"Blood"},{"key":"22_CR17_22","first-page":"326","volume":"90","author":"A.H Elmaagacli","year":"2005","unstructured":"Elmaagacli, A.H., Koldehoff, M., Peceny, R., et al. (2005) WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Haematologica 90, 326\u2013334.","journal-title":"Haematologica"},{"key":"22_CR18_22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10238-006-0093-8","volume":"6","author":"M Koldehoff","year":"2006","unstructured":"Koldehoff, M., Steckel, N.K., Beelen, D.W., et al. (2006) Synthetics mall interfering RNAs reduce bcr-abl gene expression in leukaemic cells of de novo Philadelphia (+) acute myeloid leukemia. Clin. Exp. Med. 6, 45\u201347.","journal-title":"Clin. Exp. Med"},{"key":"22_CR19_22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00109-004-0558-8","volume":"82","author":"C.R Dass","year":"2004","unstructured":"Dass, C.R. (2004) Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection. J. Mol. Med. 82, 579\u2013591.","journal-title":"J. Mol. Med"},{"key":"22_CR20_22","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.addr.2003.10.037","volume":"56","author":"E Fattal","year":"2004","unstructured":"Fattal, E., Couvreur, P., and Dubernet, C. (2004) \u201cSmart\u201d delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv. Drug Delivery Rev. 56, 931\u2013946.","journal-title":"Adv. Drug Delivery Rev"},{"key":"22_CR21_22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10238-007-0125-z","volume":"7","author":"M Koldehoff","year":"2007","unstructured":"Koldehoff, M., Steckel, N.K., Beelen, D.W., et al. (2007) Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin. Exp. Med. 7, 47\u201355.","journal-title":"Clin. Exp. Med"},{"key":"22_CR22_22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrd2310","volume":"6","author":"A de Fougerolles","year":"2007","unstructured":"de Fougerolles, A., Vornlocher, H.P., Maraganore, J., et al. (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6, 443\u2013453.","journal-title":"Nat. Rev. Drug Discov"},{"key":"22_CR23_22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2133\/dmpk.22.142","volume":"22","author":"S. Kawakami","year":"2007","unstructured":"Kawakami, S. and Hashida, M. (2007) Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab. Pharmacokinet. 22, 142\u2013151.","journal-title":"Drug Metab. Pharmacokinet"},{"key":"22_CR24_22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nature03121","volume":"432","author":"J Soutschek","year":"2004","unstructured":"Soutschek, J., Akinc, A., Bramlage, B., et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173\u2013178.","journal-title":"Nature"},{"key":"22_CR25_22","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/nbt1122","volume":"23","author":"D.V Morrissey","year":"2005","unstructured":"Morrissey, D.V., Lockridge, J.A., Shaw, L., et al. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002\u20131007.","journal-title":"Nat. Biotechnol"},{"key":"22_CR26_22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nbt1101","volume":"23","author":"E Song","year":"2005","unstructured":"Song, E., Zhu, P., Lee, S.-K., et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709\u2013717.","journal-title":"Nat. Biotechnol"},{"key":"22_CR27_22","first-page":"1","volume":"1","author":"H. Sezaki","year":"1984","unstructured":"Sezaki, H. and Hashida, M. (1984) Macromolecule-drug conjugates in targeted cancer chemotherapy. Crit. Rev. Ther. Drug Carrier Syst. 1, 1\u201338.","journal-title":"Crit. Rev. Ther. Drug Carrier Syst"},{"key":"22_CR28_22","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1124\/jpet.102.036749","volume":"303","author":"K.L Sewell","year":"2002","unstructured":"Sewell, K.L., Geary, R.S., Baker, B.F., . et al. (2002) Phase I trial of ISIS 104838, a 2. \u2032-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-\u03b1 J. Pharma. Exp. Therap. 303, 1334","journal-title":"J. Pharma. Exp. Therap"},{"key":"22_CR29_22","doi-asserted-by":"publisher","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","volume":"23","author":"S.M O\u2019Brian","year":"2005","unstructured":"O\u2019Brian, S.M., Cunningham, C.C., Golenkov, A.K., et al. (2005) Phase I and II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukaemia. J. Clin. Oncol. 23, 7697\u20137702.","journal-title":"J. Clin. Oncol"},{"key":"22_CR30_22","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1093\/nar\/gkg649","volume":"31","author":"R. Kretschmer-Kazemi Far","year":"2003","unstructured":"Kretschmer-Kazemi Far, R. and Sczakiel, G. (2003) The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res. 31, 4417\u20134424.","journal-title":"Nucleic Acids Res"},{"key":"22_CR31_22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1023\/A:1010338219401","volume":"20","author":"W. Guo","year":"2000","unstructured":"Guo, W. and Lee, R.J. (2000) Efficient gene delivery using anionic liposome-complexed polyplexes (LPDII). Biosci. Rep. 20, 419\u2013432.","journal-title":"Biosci. Rep"},{"key":"22_CR32_22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbamem.2005.03.004","volume":"1711","author":"S.D Patil","year":"2005","unstructured":"Patil, S.D., Rhodes, D.G., and Burgess, D.J. (2005) Biophysical characterization of anionic lipoplexes. BBA-Biomembranes 1711, 1\u201311.","journal-title":"BBA-Biomembranes"},{"key":"22_CR33_22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cncr.11909","volume":"100","author":"R Advani","year":"2004","unstructured":"Advani, R., Peethambaram, P., Lum, B.L., et al. (2004) A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with ovarian carcinoma. Cancer 100, 321\u20136.","journal-title":"Cancer"},{"key":"22_CR34_22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1182\/blood-2002-06-1899","volume":"101","author":"G Marcucci","year":"2003","unstructured":"Marcucci, G., Byrd, J.C., Dai, G., et al. (2003) Phase 1 and pharmacodynamic studies of G3139, a BCL-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed leukemia. Blood 101, 425\u201332.","journal-title":"Blood"},{"key":"22_CR35_22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/01.moh.0000148551.93303.9e","volume":"12","author":"J Goldman","year":"2004","unstructured":"Goldman, J. (2004) Monitoring minimal residual disease in BCR-ABL. -positive chronic myeloid leukaemia in the imatinib era Curr. Opin. Hematol. 12, 33\u201339.","journal-title":"Curr. Opin. Hematol"},{"key":"22_CR36_22","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford, S., Rudzki, Z., Walsh, S., et al. (2002) High frequency of point mutation clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukaemia or Ph-positive acute lymphoblastic leukaemia who develop imatinib (STI571) resistance. Blood 99, 3472\u20133475.","journal-title":"Blood"},{"key":"22_CR37_22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford, S., Rudzki, Z., Walsch, S., et al. (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276\u2013283.","journal-title":"Blood"},{"key":"22_CR38_22","first-page":"347","volume":"1","author":"N. Dias","year":"2002","unstructured":"Dias, N. and Stein, C.A. (2002) Antisense Oligonucleotides: Basic concepts and mechanisms. Mol. Cancer Ther. 1, 347\u2013355.","journal-title":"Mol. Cancer Ther"},{"key":"22_CR39_22","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1038\/sj.onc.1205653","volume":"21","author":"M Wilda","year":"2002","unstructured":"Wilda, M., Fuchs, U., W\u00f6ssmann, W., and Borkhardt, A. (2002) Killing of leukemic cells with a BCR\/ABL fusion gene by RNA interference. Oncogene 21, 5716\u20135724.","journal-title":"Oncogene"},{"key":"22_CR40_22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm1191","volume":"11","author":"V Hornung","year":"2005","unstructured":"Hornung, V., Guenthner-Biller, M., Bourquin, C., et al. (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263\u2013270.","journal-title":"Nat. Med"},{"key":"22_CR41_22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00253-007-0984-y","volume":"76","author":"A Aigner","year":"2007","unstructured":"Aigner, A. (2007) Application of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl. Microbiol. Biotechnol. 76, 9\u201321.","journal-title":"Appl. Microbiol. Biotechnol"}],"container-title":["Methods in Molecular Biology","siRNA and miRNA Gene Silencing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-60327-547-7_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T02:12:36Z","timestamp":1676686356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-60327-547-7_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,13]]},"ISBN":["9781603275460","9781603275477"],"references-count":41,"URL":"https:\/\/doi.org\/10.1007\/978-1-60327-547-7_22","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2008,10,13]]},"assertion":[{"value":"13 October 2008","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}